AU2021349415A1 - Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy - Google Patents

Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy Download PDF

Info

Publication number
AU2021349415A1
AU2021349415A1 AU2021349415A AU2021349415A AU2021349415A1 AU 2021349415 A1 AU2021349415 A1 AU 2021349415A1 AU 2021349415 A AU2021349415 A AU 2021349415A AU 2021349415 A AU2021349415 A AU 2021349415A AU 2021349415 A1 AU2021349415 A1 AU 2021349415A1
Authority
AU
Australia
Prior art keywords
weeks
binding fragment
administered
antigen binding
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021349415A
Other languages
English (en)
Other versions
AU2021349415A9 (en
Inventor
Zachary COOPER
Judson Englert
Rakesh Kumar
Philip Lloyd MARTIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2021349415A1 publication Critical patent/AU2021349415A1/en
Publication of AU2021349415A9 publication Critical patent/AU2021349415A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2021349415A 2020-09-23 2021-09-22 Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy Abandoned AU2021349415A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063082162P 2020-09-23 2020-09-23
US63/082,162 2020-09-23
US202063084900P 2020-09-29 2020-09-29
US63/084,900 2020-09-29
PCT/IB2021/058662 WO2022064399A1 (en) 2020-09-23 2021-09-22 Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy

Publications (2)

Publication Number Publication Date
AU2021349415A1 true AU2021349415A1 (en) 2023-06-01
AU2021349415A9 AU2021349415A9 (en) 2024-05-02

Family

ID=80845024

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021349415A Abandoned AU2021349415A1 (en) 2020-09-23 2021-09-22 Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy

Country Status (10)

Country Link
US (1) US20240010746A1 (https=)
EP (1) EP4217072A4 (https=)
JP (1) JP2023542523A (https=)
KR (1) KR20230074206A (https=)
CN (1) CN116209468A (https=)
AU (1) AU2021349415A1 (https=)
BR (1) BR112023004594A2 (https=)
CA (1) CA3194926A1 (https=)
IL (1) IL301376A (https=)
WO (1) WO2022064399A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4626552A1 (en) * 2022-12-01 2025-10-08 MedImmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230038311A (ko) * 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
CN118307674A (zh) * 2017-06-22 2024-07-09 诺华股份有限公司 针对cd73的抗体分子及其用途
TWI823906B (zh) * 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
US20200317803A1 (en) * 2019-04-02 2020-10-08 Medimmune, Llc Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors

Also Published As

Publication number Publication date
JP2023542523A (ja) 2023-10-10
EP4217072A4 (en) 2024-10-16
WO2022064399A1 (en) 2022-03-31
CA3194926A1 (en) 2022-03-31
BR112023004594A2 (pt) 2023-04-11
EP4217072A1 (en) 2023-08-02
US20240010746A1 (en) 2024-01-11
IL301376A (en) 2023-05-01
KR20230074206A (ko) 2023-05-26
AU2021349415A9 (en) 2024-05-02
CN116209468A (zh) 2023-06-02

Similar Documents

Publication Publication Date Title
JP6783312B2 (ja) がんを処置するためのｏｘ４０アゴニストおよび４−１ｂｂアゴニストモノクローナル抗体の組み合わせ
JP6448533B2 (ja) Ｐｄ−１／ｐｄ−ｌ１シグナル伝達を破壊することによる癌免疫療法
JP2022046480A (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
JP6805428B2 (ja) Ｃｅａｃａｍ１に対するヒト化抗体
JP2021181482A (ja) 中枢神経系新生物における免疫チェックポイント阻害剤の使用
EP4445958B1 (en) Combination therapy for melanoma
CN107922502A (zh) 使用免疫检验点抑制剂治疗癌症的方法
JP2024028805A (ja) がん処置のための坑ｉｌ－８抗体及び坑ｐｄ－１抗体を用いる組合せ治療
CN108350081A (zh) 使用抗pd-1抗体和抗ctla-4抗体的组合治疗肺癌
TW201642897A (zh) Ｈｅｒ２結合劑治療
JP2024038034A (ja) 膀胱癌の抗ｐｄ－ｌ１抗体治療
JP2022527334A (ja) 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法
US20240010746A1 (en) Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy
EP4308243A1 (en) Methods for treating cancer with anti-ilt3 antibodies
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
KR20250112805A (ko) 항-ddr1 항체 및 면역관문 억제제를 사용한 암 치료 방법
KR20250115399A (ko) 항-ddr1 항체를 사용한 암 치료 방법
KR20250116698A (ko) Dll3-발현 암의 치료 방법
WO2023192478A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
KR20240082393A (ko) 항-갈렉틴-9 항체 및 이의 치료적 용도
WO2023170549A1 (en) Treatment methods using ctla-4 and pd-1 bispecific antibodies
HK40118859A (zh) 用於治疗肿瘤的抗-cd73、抗-pd-l1抗体和化疗

Legal Events

Date Code Title Description
SREP Specification republished
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application